Nutriband Inc., a developer of transdermal pharmaceutical products with abuse-deterrent technologies, has signed a non-binding Letter of Intent with the Qvanta Group of Companies to explore potential collaboration in advanced technology solutions. The parties aim to evaluate secure AI and analytics platforms for regulated pharmaceutical data, cybersecurity frameworks for abuse-deterrent technologies, and advanced modeling capabilities utilizing quantum-ready infrastructure. The agreement is exploratory and does not constitute a formal partnership or binding commercial relationship at this stage, with any future collaboration subject to further technical and regulatory review and definitive agreements.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutriband Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9604213) on December 18, 2025, and is solely responsible for the information contained therein.